Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

GELNIQUE Drug Profile

« Back to Dashboard

What is the patent landscape for Gelnique, and when can generic versions of Gelnique launch?

Gelnique is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-four patent family members in twenty countries.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for Tradename: GELNIQUE

Patents:5
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list100
Clinical Trials: see list2
Patent Applications: see list1,304
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GELNIQUE at DailyMed

Pharmacology for Tradename: GELNIQUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes7,029,694► SubscribeY ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo7,179,483► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes8,920,392► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo8,241,662► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes7,179,483► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot